Scalable Expanded Access With Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS

Summary

The purpose of this Expanded Access Program is to provide MN-166 (ibudilast) to ALS patients who are not eligible for an enrolling ALS clinical trial. This Expanded Access Program will assess if MN-166 can help people with ALS in slowing down the progression of the disease.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications